Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study

被引:84
|
作者
Shin, Ju-Young [1 ,2 ,3 ,4 ]
Roughead, Elizabeth E. [5 ]
Park, Byung-Joo [6 ]
Pratt, Nicole L. [5 ]
机构
[1] McGill Univ, Jewish Gen Hosp, Lady Davis Res Inst, Ctr Clin Epidemiol, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Dept Epidemiol, Montreal, PQ, Canada
[3] McGill Univ, Dept Biostat, Montreal, PQ, Canada
[4] McGill Univ, Dept Occupat Hlth, Montreal, PQ, Canada
[5] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia
[6] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea
来源
BMJ-BRITISH MEDICAL JOURNAL | 2016年 / 353卷
基金
澳大利亚国家健康与医学研究理事会;
关键词
NERVOUS-SYSTEM STIMULANTS; AMBULATORY BLOOD-PRESSURE; RISK; EVENTS; ADOLESCENTS; MEDICATIONS; DESIGNS; DRUGS; DEATH;
D O I
10.1136/bmj.i2550
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To determine whether treatment with methylphenidate in children and young people with attention-deficit/hyperactivity disorder (ADHD) was associated with cardiovascular events. DESIGN Self controlled case series analysis. SETTING Nationwide health insurance database, 1 January 2008 to 31 December 2011, in South Korea. PARTICIPANTS 1224 patients aged <= 17 who had experienced an incident cardiovascular event and had had at least one incident prescription for methylphenidate. MAIN OUTCOME MEASURES A recorded diagnosis (either a primary or secondary cause) of any of the following cardiovascular adverse events: arrhythmias (ICD-10 (international classification of diseases, 10th revision) codes I44, I45, I47, I48, I49), hypertension (codes I10-I15), myocardial infarction (code I21), ischemic stroke (code I63), or heart failure (code I50). Incidence rate ratios were calculated with conditional Poisson regression and adjusted for time varying comorbidity and comedication. RESULTS Increased risk of arrhythmia was observed in all exposed time periods-that is, periods of treatment with methylphenidate-(incidence rate ratio 1.61, 95% confidence interval 1.48 to 1.74), and the risk was highest in the children who had congenital heart disease. No significant risk of myocardial infarction was observed for all exposed time periods (1.33, 0.90 to 1.98), though risk was higher in the early risk periods between eight and 56 days after the start of treatment with methylphenidate. No significant increased risk was observed for hypertension, ischemic stroke, or heart failure. CONCLUSION The relative risk of myocardial infarction and arrhythmias is increased in the early period after the start of methylphenidate treatment for ADHD in children and young people. Though the absolute risk is likely to be low, the risk-benefit balance of methylphenidate should be carefully considered, particularly in children with mild ADHD.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Cardiovascular Safety of Atomoxetine and Methylphenidate in Patients With Attention-Deficit/Hyperactivity Disorder in Japan: A Self-Controlled Case Series Study
    Zheng, Yunlong
    Fukasawa, Toshiki
    Yamaguchi, Fumitaka
    Takeuchi, Masato
    Kawakami, Koji
    JOURNAL OF ATTENTION DISORDERS, 2024, 28 (04) : 439 - 450
  • [2] Evaluation of Cardiovascular Effects of Methylphenidate in Children with Attention-deficit Hyperactivity Disorder
    Simsek, Ayse
    Akin, Elif
    Gerceker, Engin
    Anil, Murat
    JOURNAL OF DR BEHCET UZ CHILDRENS HOSPITAL, 2022, 12 (03): : 205 - 210
  • [3] Cardiovascular Safety of Stimulants in Children with Attention-Deficit/Hyperactivity Disorder: A Nationwide Prospective Cohort Study
    Dalsgaard, Soren
    Kvist, Anette Primdal
    Leckman, James F.
    Nielsen, Helena Skyt
    Simonsen, Marianne
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2014, 24 (06) : 302 - 310
  • [4] Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry
    Cortese, Samuele
    Panei, Pietro
    Arcieri, Romano
    Germinario, Elena A. P.
    Capuano, Annalisa
    Margari, Lucia
    Chiarotti, Flavia
    Curatolo, Paolo
    CNS DRUGS, 2015, 29 (10) : 865 - 877
  • [5] Early Cardiovascular Evaluation after Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder
    Cilsal, Erman
    Yurtcu, Eray
    Elatas, Aygul
    GAZI MEDICAL JOURNAL, 2020, 31 (03): : 345 - 348
  • [6] Methylphenidate and the risk of burn injury among children with attention-deficit/hyperactivity disorder
    Chen, Vincent Chin-Hung
    Yang, Yao-Hsu
    Kuo, Ting Yu
    Lu, Mong-Liang
    Tseng, Wei-Ting
    Hou, Tsai-Yu
    Yeh, Jia-Ying
    Lee, Charles Tzu-Chi
    Chen, Yi-Lung
    Lee, Min-Jing
    Dewey, Michael E.
    Gossop, Michael
    EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES, 2020, 29
  • [7] Methylphenidate Treatment and Dyskinesia in Children with Attention-Deficit/Hyperactivity Disorder
    Balazs, Judit
    Dallos, Gyoengyver
    Kereszteny, Agnes
    Czobor, Pal
    Gadoros, Julia
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2011, 21 (02) : 133 - 138
  • [8] Traffic Violations among Young People with Attention-Deficit Hyperactivity Disorder
    Ferro, Mark A.
    Leatherdale, Scott T.
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2019, 64 (07): : 511 - 515
  • [9] Retrospective Accounts of Self-Stigma Experienced by Young People With Attention-Deficit/Hyperactivity Disorder (ADHD) or Depression
    McKeague, Lynn
    Hennessy, Eilis
    O'Driscoll, Claire
    Heary, Caroline
    PSYCHIATRIC REHABILITATION JOURNAL, 2015, 38 (02) : 158 - 163
  • [10] Risperidone Versus Methylphenidate in Treatment of Preschool Children With Attention-Deficit Hyperactivity Disorder
    Arabgol, Fariba
    Panaghi, Leily
    Nikzad, Vahid
    IRANIAN JOURNAL OF PEDIATRICS, 2015, 25 (01)